

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2019/243898 A8

(43) International Publication Date
26 December 2019 (26.12.2019)

WIPO | PCT

(51) International Patent Classification:

C07K 16/24 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2019/000806

(22) International Filing Date:

17 June 2019 (17.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18382431.7 18 June 2018 (18.06.2018) EP
19382131.1 22 February 2019 (22.02.2019) EP

(71) Applicants: **MOSAIC BIOMEDICALS SLU** [ES/ES]; Barcelona Science Park, C/baldiri Reixac, 4-8, Torre "i" 7a Planta, 08028 Barcelona (ES). **FUNDACIÓ PRIVADA INSTITUT D' INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON** [ES/ES]; Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **FUNDACIÓ PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS** [ES/ES]; Passeig Lluís Companys, 23, 08010 Barcelona (ES).

(72) Inventors: **SEOANE SUAREZ, Joan**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **ANIDO FOLGUEIRA, Judit**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **HALLETT, Robin, Matthew**; 101 College Street, Tmdt 11-301, Toronto, ON M5G 1L5 (CA). **BAYLISS, Peter, Edward**; 101 College Street, Tmdt 11-301, Toronto, ON M5G 1L7 (CA). **JE-**

GANATHAN, Ajitha; 101 College Street, Tmdt 11-301, Toronto, ON M5G 1L7 (CA). **GIBLIN, Patricia, Anne**; 1 Marina Park Drive, Suite 1401, Boston, MA 02210 (US). **HUBER RUANO, Isabel**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **MAGRAM, Jeanne**; 1 Marina Park Drive, Suite 1401, Boston, MA 02210 (US). **PASCUAL GARCIA, Monica**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **BONFILL TEIXIDOR, Ester**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **PLANAS RIGOL, Ester**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER




Fig. 20I

(57) Abstract: Described herein are methods of selecting and treating patients likely to respond to treatment with an anti-LIF antibody.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

13 February 2020 (13.02.2020)

(48) Date of publication of this corrected version:

24 September 2020 (24.09.2020)

(15) Information about Correction:

see Notice of 24 September 2020 (24.09.2020)